Difference between revisions of "Aldesleukin (Proleukin)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "manufacturer. Instead" to "manufacturer. Instead")
m
Line 7: Line 7:
  
 
==Diseases for which it is used==
 
==Diseases for which it is used==
*[[Bone sarcoma]]
 
 
*[[Melanoma]]
 
*[[Melanoma]]
 +
*[[Neuroblastoma]]
 +
*[[Osteosarcoma]]
 
*[[Renal cancer]]
 
*[[Renal cancer]]
  
Line 31: Line 32:
 
[[Category:T-cell activators]]
 
[[Category:T-cell activators]]
  
[[Category:Bone sarcoma medications]]  
+
[[Category:Melanoma medications]]
[[Category:Melanoma medications]]  
+
[[Category:Neuroblastoma medications]]  
 +
[[Category:Osteosarcoma medications]]  
 
[[Category:Renal cancer medications]]
 
[[Category:Renal cancer medications]]
  
 
[[Category:Drugs FDA approved in 1992]]
 
[[Category:Drugs FDA approved in 1992]]

Revision as of 01:29, 28 January 2018

General information

Class/mechanism: Recombinant interleukin-2 which activates the immune system. Aldesleukin encourages growth of IL-2 dependent cells, triggers natural killer (NK) and lymphokine-activated killer (LAK) cell activity, induces production of interferon gamma, and increases lymphocyte cytotoxicity.[1][2][3]
Route: IV
Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

  • 5/5/1992: Initial FDA approval

Also known as

  • Generic names: Interleukin-2, IL-2
  • Brand names: Macrolin, Proleukin

References